Google is developing cancer and heart attack detector

Google is developing cancer and heart attack detector

WristbandGoogle hopes to develop a wristband that would carry out non-invasive blood tests
Google is aiming to diagnose cancers, impending heart attacks or strokes and other diseases, at a much earlier stage than is currently possible.
The company is working on technology that combines disease-detecting nanoparticles, which would enter a patient's bloodstream via a swallowed pill, with a wrist-worn sensor.
The idea is to identify slight changes in the person's biochemistry that could act as an early warning system.
The work is still at an early stage.
Early diagnosis is the key to treating disease. Many cancers, such as pancreatic, are detected only after they have become untreatable and fatal.
There are marked differences between cancerous and healthy tissues.
Google's ambition is to constantly monitor the blood for the unique traces of cancer, allowing diagnosis long before any physical symptoms appear.
The project is being conducted by the search company's research unit, Google X, which is dedicated to investigating potentially revolutionary innovations.
Andrew Conrad and Google Life Sciences teamMr Conrad, seen on the left, joined Google X as head of Life Sciences in 2013
It marks the firm's latest shift into the medical sector following its work on glucose-measuring contact lenses for patients with diabetes and the acquisition of a start-up that developed a spoon to counteract the tremors caused by Parkinson's disease.
Google has also bought stakes in Calico, an anti-ageing research company, and 23andMe, which offers personal genetic-testing kits.
Nanoparticles
The diagnostic project is being led by Dr Andrew Conrad, a molecular biologist who previously developed a cheap HIV test that has become widely used.
"What we are trying to do is change medicine from reactive and transactional to proactive and preventative," he told the BBC.

“Start Quote

Doctor-patient relationships are pretty privileged and would not involve Google in any way”
Dr Andrew ConradGoogle X
"Nanoparticles... give you the ability to explore the body at a molecular and cellular level."
Google is designing a suite of nanoparticles which are intended to match markers for different conditions.
They could be tailored to stick to a cancerous cell or a fragment of cancerous DNA.
Or they could find evidence of fatty plaques about to break free from the lining of blood vessels. These can cause a heart attack or stroke if they stop the flow of blood.
Another set would constantly monitor chemicals in the blood.
High levels of potassium are linked to kidney disease. Google believes it will be possible to construct porous nanoparticles that alter colour as potassium passes through.
"Then [you can] recall those nanoparticles to a single location - because they are magnetic - and that location is the superficial vasculature of the wrist, [where] you can ask them what they saw," said Dr Conrad.
Unattached nanoparticles would move differently in a magnetic field from those clumped around a cancer cell.
In theory, software could then provide a diagnosis by studying their movements.
As part of the project, the researchers have also explored ways of using magnetism to concentrate the nanoparticles temporarily in a single area.
The tech company's ambition is ultimately to create a wristband that would take readings of the nanoparticles via light and radio waves one or more times a day.
Google graphic
Prof Paul Workman, chief executive of the Institute of Cancer Research in London, told the BBC News website: "In principle this is great. Any newcomers with new ideas are welcome in the field.
"There is an urgent need for this. If we can detect cancer or other diseases earlier, then we can intervene with either lifestyle changes or treatment.
"How much of this proposal is dream versus reality is impossible to tell because it is a fascinating concept that now needs to be converted to practice."
His team at the institute is investigating cancer cells and cancer DNA in the blood as new methods of diagnosis and planning treatment.
He did warn Google that a diagnosis could increase anxiety and lead to unnecessary treatment, so there needed to be "very careful and rigorous analysis" before this type of blood monitoring could be used widely.
The scheme is being made public because Google is now seeking to establish partnerships.
But Dr Conrad sought to play down the idea that his firm wanted to run a search tool for the human body, alongside the one it already offers for the internet.
"We are the inventors of the technology but we have no intentions of commercialising it or monetising it in that way," he said.
"We will license it out and the partners will take it forward to doctors and patients.
"These are not consumer devices. They are prescriptive medical devices, and you know that doctor-patient relationships are pretty privileged and would not involve Google in any way."
line
Analysis: James Gallagher, health editor
Health graphic
From searching the internet to searching your blood, Google certainly has high ambitions. But is it feasible?
The basic principles are sound and mirror the work already taking place around the world.
Many research groups are looking at bits of cancer floating in the blood as a better way of diagnosing the disease and also to assess which tumours are more aggressive.
But Google will have to address concerns around "false positives", when healthy people are told they are ill.
These have plagued the PSA test for prostate cancer, as PSA levels can soar even when cancer is absent.
There is also the issue of "over-diagnosis". Who needs treating even if a condition is discovered?
There is continuing controversy around breast cancer screening: for every life saved, three women have invasive treatment for a cancer that would never have proved fatal.
Screening the body for disease is littered with dangers, and if it is not done carefully, it could make hypochondriacs out of all of us.
line
Big risk?
The nanoparticle project is the latest so-called "moonshot" to originate from Google X.
Other schemes include the firm's driverless car effort and Project Loon, an attempt to provide internet access to remote areas via a network of high-altitude weather balloons.
While such ideas have the potential to make money, there is also a high risk of failure, and Google X acknowledges that several of its ideas have been ditched before being made public.
One analyst commented that its parent was in a rare position to make such investments.
"Under normal circumstances this is the kind of thing that would worry investors because such projects are too long-term and the miss rate is too high," said Cyrus Mewawalla, from CM Research.
"But because Google's core search business is currently so strong, shareholders are not worried at the moment and are allowing the firm to take a gamble."
line
Analysis: Leo Kelion, technology desk editor
icons
Google's diagnostic project may never come to fruition, but its significance lies in the fact it represents part of a wider push by the firm into health tech.
Bearing in mind this is already a crowded sector, it begs the question: why?
The search firm denies that it wants to run its own diagnosis service, with all the privacy headaches that would entail, but the patents it creates along the way could prove lucrative.
No doubt the fact that co-founder and Google X chief Sergey Brin has been told that a gene mutation has increased his likelihood of contracting Parkinson's has also focused efforts.
And the company clearly believes its expertise in "big data" analysis and its freedom to focus on giant leaps forward, rather than incremental steps, plays to its advantages.
It's worth remembering that another much hyped health idea, Google Flu Trends - which aimed to predict the spread of the virus based on internet searches - has been dubbed a failure by some after researchers said it had overestimated the number of cases in 100 out of 108 weeks.
And US health watchdogs banned Google-backed 23andme from selling the the heath data part of its genetic screening kits last year.
On the other hand, Google's "smart lens" for diabetics shows promise, with Swiss firm Novartis stepping up to license the technology in July.
And the forthcoming Android Fit platform, designed to harness data from other apps and wearables, has a good chance of success given the huge number of people using the operating system.

Ebola outbreak: UK aid ship docks in Sierra Leone

Andrew Harding says RFA Argus is "getting ready to unload 32 pickup trucks and three helicopters"
A UK ship has arrived in Sierra Leone to help deal with the deadly Ebola outbreak in the West African country.
Royal Fleet Auxiliary Argus is carrying food, medical equipment and 32 pick-up trucks, to help keep hard-pressed Ebola treatment centres going.
Doctors, nurses and military personnel are also on board. The ship has docked in the capital, Freetown.
Ebola has killed nearly 5,000 people and infected more than 10,000 in West Africa since March.
RFA Argus set sail from Falmouth in Cornwall on 17 October, also carrying three Royal Navy Merlin helicopters. The BBC's Africa correspondent Andrew Harding said it would act as an offshore base for the aid effort.

RFA Argus in numbers

  • 100 hospital beds
  • 3 Merlin helicopters
  • 350 crew, including:
  • 83 medics and
  • 80 Royal Marines
GETTY
At 28,000 tonnes, the ship is one of the Royal Navy's larger support vessels, but despite having its own onboard hospital, it will not be used to directly treat anyone who has come into contact with the virus.
If any of the crew or the Royal Marines on board become infected they would be kept in isolation, and then taken to one of the clinics on the ground.

RFA Argus
RFA Argus
  • Part of the Royal Fleet Auxiliary - which is a civilian-staffed fleet of vessels owned by the Ministry of Defence
  • Principal role is as a "Primary Casualty Receiving Ship". Has an emergency department, resuscitation and surgical facilities, radiology suite including CT scanner, critical care unit, high dependency unit and general ward of around 70 beds
  • Fitted with self-defence guns, with secondary role to provide specialist aviation training
  • Main task of RFA ships is to supply Royal Navy warships with fuel, food, stores and ammunition
line
The ship also transported 35 pallets of ration packs, more than 5,000 bottles of water, and a water osmosis plant, the Royal Navy said.
Speaking from Freetown, RFA Argus commanding officer Captain David Eagles said the helicopters were a "game changer" in the fight against the disease.
"To be able to fly equipment and experts right into the heart of the areas it is needed will be a fundamental change in the way we do business. It will give the effort ashore much greater agility and velocity to deliver the mission," he told Sky News.
"For the people on-board the ship, it is just simply a case of rolling up their sleeves and getting in and contributing as best we can, and our people are very much looking forward to that."
A helicopter aboard the RFA ArgusThe RFA Argus can carry three Royal Navy Merlin helicopters
The UK is leading the international response to the disease in Sierra Leone, where it has pledged £205m in aid.
In all, the UK is deploying about 750 military personnel to help tackle Ebola in Sierra Leone, the Ministry of Defence has said.
Defence Secretary Michael Fallon has described the RFA Argus mission as a sign of the nation's "determination to lead the world's efforts to tackle the Ebola crisis".
There is no cure or vaccine for Ebola, which is transmitted through sweat, blood and saliva, and has a 21-day incubation period.
An appeal for the Ebola crisis in West Africa has been launched by the Disasters Emergency Committee (DEC), and it marks the first time the committee - a group of 13 UK aid charities - has sought funds over a disease outbreak.
Appeals will be made by all the main UK broadcasters on Thursday, and the government has said it will match the first £5m of donations made by the public to the DEC appeal.
More than 13,700 people have been sickened in the Ebola outbreak, the vast majority in Liberia, Sierra Leone and Guinea.

Ebola virus disease (EVD)
  • Symptoms include high fever, bleeding and central nervous system damage
  • Spread by body fluids, such as blood and saliva
  • Fatality rate can reach 90% - but current outbreak has mortality rate of about 70%
  • No proven vaccine or cure
  • Fruit bats, a delicacy for some West Africans, are considered to be virus's natural host

Çağımızın Vebası sosyal medya !




İŞTE O YAZI:
Kaç kere söyledik: Twitter, Instagram ve benzeri "sanal mekânlar" çağımızın vebası oldu.
Bu tür yerler, çarpık beyinli ruh hastalarının ruh pisliklerini boca ettikleri birer çöp tenekesi haline geldi. Kendi adının arkasında duramayan zavallı asosyal, acınası sosyopat, kendini gizleyerek, maske takarak oraya aklına geleni, ağzına geleni döşeniyor. Ve böylece boşalıyor.
Nitekim Gezi ayaklanmasında da, paralel çetenin çevirdiği dolaplarda da bu sanal ortamlar bol bol kullanıldı.    
Ruh hastalarına bir de çapsız hınzırlar eklendi.
Ruh çöpünü boşaltıp rahatlamanın yanısıra yalan yayma ve kışkırtma amaçlı da kullanıldı bu ortamlar.
(...) Cumhurbaşkanına sövenler mi ararsınız, haşa sümme haşa Cenab-ı Allah'a küfür edenler mi? (...)              
ENGİN ARDIÇ      

Diyarbakır'da Askere Silahlı Saldırı


Diyarbakır'ın merkez Bağlar ilçesinde bir astsubay maskeli kişilerin silahlı saldırısı sonucu başından vurularak ağır yaralandı.

BAŞINDAN VURULDU
Olay, Diyarbakır'ın merkez Bağlar İlçesi Körhat Caddesi üzerinde Çarşamba günleri kurulan semt pazarında bugün saat 16.30 sıralarında meydana geldi. Diyarbakır 8'inci Ana Jet Üssü Komutanlığı'nda görevli olduğu belirtilen ve adı henüz açıklanmayan astsubay yanında eşi ile birlikte pazarda alışveriş yaparken, arkadan yaklaşan ve yüzleri maske ile kapalı 2 kişinin silahlı saldırısına uğradı. Saldırganların başına silahla ateş açtığı astsubay ağır yaralandı.
DURUMU AĞIR
Saldırganlar kaçarken, astsubaya ilk müdahalesevk edilen 112 Acil Servis ekipleri tarafından yapıldı. Dicle Üniversitesi Tıp Fakültesi Hastanesi'ne kaldırılan astsubayın durumunun ağır olduğu belirtildi.
Polis, saldırganları yakalamak için kapsamlı operasyon başlattı. Bölgeye çok sayıda Özel Harakat timi sevk edildi.

Zambian President Sata death: White interim leader appointed







Zambian Vice-President Guy Scott has been named acting leader following the death of President Michael Sata.


Presidential elections to choose a permanent successor will be held within 90 days, Defence Minister Edgar Lungu said.
Mr Scott becomes Africa's first white head of state since FW de Klerk in apartheid South Africa.
Mr Sata died in the UK aged 77 after receiving treatment for an undisclosed illness.
A look back at Zambian President Michael Sata's life
He was being treated at London's King Edward VII hospital where he died on Tuesday night.
'Beloved comrade'
Mr Scott regularly stood in for the president at official events, but was never appointed acting president when Mr Sata was abroad - so this is his first time to officially lead the country.

Guy Scott
  • Often disparagingly referred to as the "ceremonial vice-president"
  • He was born in 1944 in Northern Rhodesia after father emigrated from Glasgow to work as a doctor on the railways
  • A Cambridge-trained economist, he entered politics in 1990 joining the MMD which won the first multiparty elections the next year
  • As agricultural minister he oversaw the recovery from a devastating drought in 1992/93
  • He joined Michael Sata's Patriotic Front (PF) in 2001
  • Appointed vice-president in September 2011 after the PF's election victory
  • As his parents were not born in Zambia a constitutional clause on parentage may nullify any attempt to run for president
Guy Scott's rise to Zambia's presidency

In a brief televised address Mr Scott confirmed his appointment.
"The period of national mourning will start today. We will miss our beloved president and comrade," Reuters news agency quotes him as saying.
The president's death comes just days after Zambia celebrated the 50th anniversary of independence from the UK.
Cabinet secretary Roland Msiska said on national TV that President Sata's wife and son were at his bedside.
Michael Sata is the second of Zambia's five presidents to die in office
He is the second Zambian leader to die in office after Levy Mwanawasa in 2008.
Earlier this month reports in Zambia said that President Sata had gone abroad for a medical check-up amid persistent speculation that he was seriously ill.

Obituary: Penny Dale, BBC's former Zambia correspondent
Mr Sata was known as "King Cobra" for his tough style of public speaking
Gravelly-voiced as a result of years of chain-smoking, Michael Sata rose to political prominence in the 1980s. He quickly earned a reputation as the hardest-working governor while in charge of Lusaka and as a populist man of action. But he was also known for his authoritarian tendencies, an abrasive manner and a sharp tongue - and his critics say his nickname of "King Cobra" was well-deserved.
A devout Catholic, Mr Sata had worked as a police officer, railway man and trade unionist during colonial rule. After independence, he also spent time in London, working as a railway porter, and, back in Zambia, with a taxidermist company.
At the fourth attempt, Mr Sata won presidential elections in 2011. At first he looked as if he would keep promises to tackle corruption and create jobs and prosperity. But his term in office was marred by a crackdown on political opposition and a decline in the economy.
He had rarely been seen in public since returning from the UN General Assembly last month, where he failed to make a scheduled speech.
After he left the country, Defence Minister Edgar Lungu was named as acting president.
Mr Scott is of Scottish descent and his parents were not born in Zambia, so he may not be able to run for president in January because a constitutional clause on parentage could nullify his candidacy.

Serious Fraud Office plans Tesco criminal investigation



The Serious Fraud Office is about to carry out a criminal investigation into accounting irregularities at Tesco, the BBC has learned.